Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Equity Average (2020 - 2022)

Atea Pharmaceuticals (AVIR) has 3 years of Equity Average data on record, last reported at $661.8 million in Q3 2022.

  • For Q3 2022, Equity Average rose 12.24% year-over-year to $661.8 million; the TTM value through Sep 2022 reached $661.8 million, up 12.24%, while the annual FY2021 figure was $628.9 million, N/A changed from the prior year.
  • Equity Average reached $661.8 million in Q3 2022 per AVIR's latest filing, down from $670.2 million in the prior quarter.
  • Across five years, Equity Average topped out at $695.0 million in Q1 2022 and bottomed at -$69.8 million in Q3 2020.
  • Average Equity Average over 3 years is $452.9 million, with a median of $590.9 million recorded in 2021.
  • Peak YoY movement for Equity Average: skyrocketed 1116.44% in 2021, then grew 12.24% in 2022.
  • A 3-year view of Equity Average shows it stood at $235.6 million in 2020, then surged by 174.04% to $645.8 million in 2021, then grew by 2.49% to $661.8 million in 2022.
  • Per Business Quant database, its latest 3 readings for Equity Average were $661.8 million in Q3 2022, $670.2 million in Q2 2022, and $695.0 million in Q1 2022.